Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 130

Sort by

Sort Order Select

Journal Articles

Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations

Blood (2025) 146 (Supplement 1): 4069.

https://doi.org/10.1182/blood-2025-4069

Published: 2025

Journal Articles

Comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus belantamab mafodotin (belamaf), bortezomib, and dexamethasone and versus belamaf, pomalidomide, and dexamethasone in patients with relapsed / refractory multiple myeloma (RRMM) previously treated with 1–3 prior lines of therapy using a matching-adjusted indirect comparison

Christopher Strouse, Surbhi Sidana, Rafael Fonseca, Joaquin Martinez-Lopez, Yaël Cohen, Binod Dhakal, Murali Janakiram, Suzy Van Sanden, João Mendes, Joris Diels, Seina Lee, Sundar Jagannath

Blood (2025) 146 (Supplement 1): 4046.

https://doi.org/10.1182/blood-2025-4046

Published: 2025

Journal Articles

Comparison of clinical outcomes in multiple myeloma patients treated with chimeric antigen receptor (CAR)-T cell therapy across clinical trials: Intention-to-treat vs. per-protocol analyses

Abhishek Janardan, Pranav Jumin, Abigail Thorgerson, Ravi Kishore Narra, Othman Akhtar, Sabarinath Radhakrishnan, Marcelo Pasquini, Binod Dhakal, Anita D'Souza, Meera Mohan

Blood (2025) 146 (Supplement 1): 2800.

https://doi.org/10.1182/blood-2025-2800

Published: 2025

Journal Articles

Cell-free CAR therapy: BCMA-CAR-T cell-derived exosomes exhibit potent anti-myeloma activity

Bin Sun, Shijing Wang, Ali Ishaq, Deepak Parashar, Sridhar Rao, Tyce Kearl, Jing Dong, Peiman Hematti, Siegfried Janz, Binod Dhakal, Fumou Sun

Blood (2025) 146 (Supplement 1): 2159.

https://doi.org/10.1182/blood-2025-2159

Published: 2025

Journal Articles

Understanding access and treatment challenges in multiple myeloma care

Caidon Iwuagwu, Binod Dhakal, Jonathan Thompson, Joselle Cook

Blood (2025) 146 (Supplement 1): 4570.

https://doi.org/10.1182/blood-2025-4570

Published: 2025

Journal Articles

A machine learning model to predict risk of infection in patients receiving bispecific antibody therapy for multiple myeloma

Nicholas Semenkovich, Anand George, Aishee Bag, Mansi Shah, Sabarinath Radhakrishnan, Binod Dhakal, Samer Al Hadidi, Rajshekhar Chakraborty, Carolina Schinke, Anita D'Souza, Aniko Szabo, Meera Mohan

Blood (2025) 146 (Supplement 1): 2226.

https://doi.org/10.1182/blood-2025-2226

Published: 2025

Journal Articles

Prospective real-world evaluation of SKY92 for risk stratification in multiple myeloma: Comparison with updated ims/IMWG criteria in the prommis study

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, Raja Prince-Eladnani, Ajay Nooka, David Vesole, Barry Paul, Parameswaran Hari, Silvia D'Ambrosi, Rowan Kuiper, Martin Van Vliet, David Siegel, Saad Usmani, Frits van Rhee

Blood (2025) 146 (Supplement 1): 2220.

https://doi.org/10.1182/blood-2025-2220

Published: 2025

Journal Articles

Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 2215.

https://doi.org/10.1182/blood-2025-2215

Published: 2025

Journal Articles

Kinetics of circulating multiple myeloma cells (CMMCs) in patients undergoing standard-of-care anti-BCMA chimeric antigen receptor T cell therapy for Relapsed/Refractory multiple myeloma

Michael Slade, Julie Fortier, Mark Fiala, Binod Dhakal, Hans Lee, Frank Kuhr, Wojciech Swat, Paola Tononi, Nicolo Manaresi, Alberto Ferrarini, Sarah Kelley, Mark Schroeder, Keith Stockerl-Goldstein, Ravi Vij

Blood (2025) 146 (Supplement 1): 5851.

https://doi.org/10.1182/blood-2025-5851

Published: 2025

Journal Articles

Ultra high-risk multiple myeloma with early mortality despite quad-class and BCMA-directed therapies: Clinical and molecular insights

Binod Dhakal, Maria Hintzke, Othman Akhtar, Jamila Mammadova, Adetola Kassim, Marcelo Pasquini, Meera Mohan, Ravi Kishore Narra, Sabarinath Radhakrishnan, Fumou Sun, Anita D'Souza, Maher Albitar, Bhagirathbhai Dholaria

Blood (2025) 146 (Supplement 1): 2240.

https://doi.org/10.1182/blood-2025-2240

Published: 2025

Journal Articles

Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma

Hang Quach, Rakesh Popat, Wenming Chen, Mary Kwok, Andrew Yee, Zhongxing Jiang, Flávia Xavier, Natalie Callander, Man Yuk Ho, Susan Bal, Michael Low, Douglas Sborov, Gabriel Man, Huan Cheng, Adam Idoine, Xin Wang, Amit Agarwal, Binod Dhakal

Blood (2025) 146 (Supplement 1): 102.

https://doi.org/10.1182/blood-2025-102

Published: 2025

Journal Articles

Redefining function high-risk (FHR) multiple myeloma (MM) in the context of upfront quadruplet (QUAD) therapy and autologous stem cell transplantation (ASCT)

Luciano Costa, Susan Bal, Kelly Godby, Gayathri Ravi, Eva Medvedova, Natalie Callander, Rebecca Silbermann, Bhagirathbhai Dholaria, Forest Huls, Baylie Mullinax, Laura Joiner, Caitlin Hagedorn, Binod Dhakal

Blood (2025) 146 (Supplement 1): 1037.

https://doi.org/10.1182/blood-2025-1037

Published: 2025

Journal Articles

Outcomes of stem cell boost (SCB) versus supportive care alone for prolonged cytopenias after chimeric antigen receptor T cell therapy (CAR-T) in relapsed/refractory multiple myeloma (RRMM): A muli-center real-world analysis

Blood (2025) 146 (Supplement 1): 1035.

https://doi.org/10.1182/blood-2025-1035

Published: 2025

Journal Articles

Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine–1

Blood (2025) 146 (Supplement 1): 256.

https://doi.org/10.1182/blood-2025-256

Published: 2025

Journal Articles

Immune restoration in long-term myeloma survival revealed by single-cell RNA-sequencing

Khanmi Kasomva, Kirthi Pulakanti, Josiah Murray, Kritika Yadav, Ravi Narra, Marcelo Pasquini, Anita D'Souza, Meera Mohan, Othman Akhtar, Deepak Parashar, Fumou Sun, Siegfried Janz, Binod Dhakal, Sridhar Rao

Blood (2025) 146 (Supplement 1): 5716.

https://doi.org/10.1182/blood-2025-5716

Published: 2025

Journal Articles

A multimodal machine learning framework to predict treatment duration in multiple myeloma patients

Frederick Shi, Xinyi Yang, Juan Li, Shijing Wang, Bin Sun, Jing Dong, Peiman Hematti, Siegfried Janz, Anita D'Souza, Laura Michaelis, Binod Dhakal, Fumou Sun

Blood (2025) 146 (Supplement 1): 5715.

https://doi.org/10.1182/blood-2025-5715

Published: 2025

Journal Articles

Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study

Blood (2025) 146 (Supplement 1): 269.

https://doi.org/10.1182/blood-2025-269

Published: 2025

Journal Articles

Characteristics of patients with Relapsed/Refractory multiple myeloma (RRMM) in europe and the US

Binod Dhakal, Victoria Benson, Astrid McKeown, Linda Kalilani, Amber Simpson, Amanda Ribbands, Annabel Lambert, Rafael Fonseca

Blood (2025) 146 (Supplement 1): 7515.

https://doi.org/10.1182/blood-2025-7515

Published: 2025

Journal Articles

CLPTM1L: A candidate therapeutic target in multiple myeloma

Swadha Pandey, Sandhya Rai, Ansul Sharma, Aishwarya Sharma, Saurabh Gupta, Fumou Sun, Amit Mitra, Jing Dong, Sridhar Rao, Binod Dhakal, Michael James, Siegfried Janz, Deepak Parashar

Blood (2025) 146 (Supplement 1): 7457.

https://doi.org/10.1182/blood-2025-7457

Published: 2025

Journal Articles

High tolerability and favorable early outcomes with full-dose lenalidomide in older adults with newly diagnosed multiple myeloma on triplet and quadruplet therapies

Stephanie Yohay, Soyoung Kim, Mingqian Lin, Temitope Oloyede, Ravi Narra, Sabarinath Radhakrishnan, Meera Mohan, Binod Dhakal, Marcelo Pasquini, Anita D'Souza, Othman Akhtar

Blood (2025) 146 (Supplement 1): 6360.

https://doi.org/10.1182/blood-2025-6360

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations

Comparison of clinical outcomes in multiple myeloma patients treated with chimeric antigen receptor (CAR)-T cell therapy across clinical trials: Intention-to-treat vs. per-protocol analyses

Cell-free CAR therapy: BCMA-CAR-T cell-derived exosomes exhibit potent anti-myeloma activity

Understanding access and treatment challenges in multiple myeloma care

A machine learning model to predict risk of infection in patients receiving bispecific antibody therapy for multiple myeloma

Prospective real-world evaluation of SKY92 for risk stratification in multiple myeloma: Comparison with updated ims/IMWG criteria in the prommis study

Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma

Kinetics of circulating multiple myeloma cells (CMMCs) in patients undergoing standard-of-care anti-BCMA chimeric antigen receptor T cell therapy for Relapsed/Refractory multiple myeloma

Ultra high-risk multiple myeloma with early mortality despite quad-class and BCMA-directed therapies: Clinical and molecular insights

Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma

Redefining function high-risk (FHR) multiple myeloma (MM) in the context of upfront quadruplet (QUAD) therapy and autologous stem cell transplantation (ASCT)

Outcomes of stem cell boost (SCB) versus supportive care alone for prolonged cytopenias after chimeric antigen receptor T cell therapy (CAR-T) in relapsed/refractory multiple myeloma (RRMM): A muli-center real-world analysis

Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine–1

Immune restoration in long-term myeloma survival revealed by single-cell RNA-sequencing

A multimodal machine learning framework to predict treatment duration in multiple myeloma patients

Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study

Characteristics of patients with Relapsed/Refractory multiple myeloma (RRMM) in europe and the US

CLPTM1L: A candidate therapeutic target in multiple myeloma

High tolerability and favorable early outcomes with full-dose lenalidomide in older adults with newly diagnosed multiple myeloma on triplet and quadruplet therapies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only